৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Products
Payment
Delivery
Roxatat (Roxadustat) is indicated for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adult patients.
Roxatat is a first-in-class, orally administered HIF-PH (Hypoxia-Inducible Factor Prolyl Hydroxylase) inhibitor that stimulates erythropoiesis by increasing the body's natural production of erythropoietin (EPO). It also improves iron regulation and counteracts the inflammation-related suppression of hemoglobin synthesis and red blood cell production by reducing hepcidin levels.
Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) with anti-anemic properties.
After administration, roxadustat inhibits the HIF-PH enzyme, which normally degrades HIF transcription factors under normal oxygen conditions. By preventing HIF degradation, roxadustat enhances HIF activity, leading to:
HIF regulates genes involved in response to low oxygen levels, including genes responsible for erythropoiesis and iron metabolism.
Clinical studies have shown that roxadustat promotes coordinated erythropoiesis, increases red blood cell counts, and maintains plasma erythropoietin concentrations within or close to the normal physiological range, even in CKD patients with inflammation and without the need for supplemental intravenous iron.
Roxadustat reversibly inhibits HIF prolyl hydroxylase enzymes, thereby reducing HIF-α degradation and promoting HIF-mediated gene transcription. This activates genes involved in:
In patients with CKD-related anemia, roxadustat:
Roxadustat has also been shown to significantly reduce cholesterol levels, regardless of concomitant use of statins or other lipid-lowering medications.
Roxadustat should be taken orally three times weekly, ensuring that doses are not taken on consecutive days.
Treatment should be individualized to maintain target hemoglobin levels of 10–12 g/dL.
Adults:
Recommended initial dose based on body weight:
Adults:
Subsequent dose adjustments should be based on clinical response and patient condition.
When dose modification is required, doses should be adjusted according to established dose increase/decrease schedules.
After a dose adjustment:
Available tablet strengths:
20 mg → 40 mg → 50 mg → 70 mg → 100 mg → 150 mg → 200 mg → 250 mg → 300 mg → 400 mg (for dialysis patients only)
If a patient misses a dose:
Roxadustat tablets may be taken:






N/A
N/A





